EcoR1 Capital LLC Makes New $1.99 Million Investment in CAMP4 Therapeutics Corporation $CAMP

EcoR1 Capital LLC bought a new stake in shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 325,000 shares of the Wireless communications provider’s stock, valued at approximately $1,992,000. CAMP4 Therapeutics comprises about 0.1% of EcoR1 Capital LLC’s investment portfolio, making the stock its 27th largest holding. EcoR1 Capital LLC owned about 0.69% of CAMP4 Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. bought a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at about $61,000. Jefferies Financial Group Inc. purchased a new position in shares of CAMP4 Therapeutics in the fourth quarter worth $70,000. Bank of America Corp DE bought a new stake in CAMP4 Therapeutics during the 4th quarter valued at $86,000. OMERS ADMINISTRATION Corp purchased a new stake in CAMP4 Therapeutics during the 4th quarter valued at $115,000. Finally, Goldman Sachs Group Inc. bought a new stake in CAMP4 Therapeutics in the 4th quarter worth $115,000.

CAMP4 Therapeutics Trading Up 0.2%

Shares of CAMP4 Therapeutics stock opened at $4.14 on Thursday. CAMP4 Therapeutics Corporation has a 12 month low of $1.30 and a 12 month high of $7.75. The firm has a market capitalization of $214.97 million, a P/E ratio of -1.75 and a beta of 0.08. The business has a fifty day simple moving average of $4.34 and a two-hundred day simple moving average of $4.70.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%.The business had revenue of $1.29 million during the quarter. Analysts predict that CAMP4 Therapeutics Corporation will post -0.82 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CAMP. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $5.00 to $9.00 in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Friday, March 6th. Rodman & Renshaw started coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price target for the company. Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st. Finally, Leerink Partners raised their target price on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, April 2nd. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.36.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.